first glp 1 medication GLP-1s were approved in 2005 for the treatment of type 2 diabetes. Over the past two decades, more versions of the have hit the market, becoming more accessible to patients and used GLP-1s were first approved in

This is a medically supervised program designed specifically to meet your individual weight loss needs

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and [PMID: 34518444] Laboratory literature summary: Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for laboratory Practice

So then, how might health plan leaders deal with what Virta terms the GLP-1 cost tsunami

Gastrointestinal Adverse Events Of the adverse effects reported during GLP-1 RA clinical trials, gastrointestinal symptoms were the most frequent, with nausea and diarrhea very common, and vomiting, constipation, abdominal pain, and dyspepsia considered to be relatively common [97]